United Homes Group stock plunges after Nikki Haley, directors resign
Investing.com -- Bayer AG’s menopause drug Lynkuet received backing from European regulators, moving closer to approval in the European Union.
The European Medicines Agency recommended approval for Lynkuet, which has demonstrated effectiveness in reducing both the frequency and severity of hot flashes in post-menopausal women. The medication is already approved for use in the UK and Canada.
The European Commission must still give final approval following the EMA recommendation. After this step, individual European countries will negotiate pricing and implement the medication’s distribution.
Lynkuet, also known by its chemical name elinzanetant, offers women an alternative to hormone treatments for managing menopause symptoms. These symptoms can disrupt sleep, affect mood, diminish quality of life, and sometimes force women to leave the workforce.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.